Sort by
Refine Your Search
-
Employer
-
Field
-
the process itself shapes disease states at cellular and molecular scales. By combining AI innovation with RNA-focused, context-aware biology, SATURNA seeks to establish actionable principles of disease
-
of sensorimotor processing. We are recruiting two postdocs: Postdoc in Computer Vision & AI for Behavior Analysis Postdoc in Embodied AI (Reinforcement Learning for Motor Control) Main duties and responsibilities
-
responsibilities The Kim Laboratory at the École Polytechnique Fédérale de Lausanne (EPFL) (https://www.epfl.ch/labs/upkim/ ) is seeking a highly motivated postdoctoral researcher to investigate how neuronal
-
(NICs) or packet processing (eBPF, XDP). Experience bringing up custom hardware boards. We offer A stimulating and international working environment Competitive salary and excellent working conditions
-
the earth sciences. NCCR Genesis does not aim to provide answers in all fields, but to drive innovative research and achieve decisive progress. Details on NCCR Genesis are available on its website https
-
conducts applied and theoretical research on the economics and politics of sustainable development, as well as the policies to achieve it. More information at: https://www.epfl.ch/labs/pasu/ . We are looking
-
will keep the position open. In that case, we are looking forward to your application after the above-mentioned deadline. Where to apply Website https://academicpositions.com/ad/empa/2026/postdoctoral
-
positions. https://www.epfl.ch/labs/entc/ Education You will work closely with Dr. Davide Bavato, head of EPFL’s recently established Entrepreneurship Education Hub. The Hub is developing a structured
-
Foster ([email protected]) - https://laser.epfl.ch/ Contract Start Date : 01.12.2026, or to be determined Activity Rate : 100.00 Contract Type: CDD Duration: 1 year, renewable Reference: 2464
-
protocols. In close collaboration with the lab of George Coukos (https://agora-cancer.ch/laboratory/coukos-lab/ ), we will derive protocols enabling rapid expansion of cancer-specific, autologous TILs